ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- HCV screening among surgical patients in a tertiary hospital of Northern China.BMC gastroenterology · 2025Article
- The Impact of COVID-19 and Related Public Health Measures on Hepatitis C Testing in Ontario, Canada.Viruses · 2025Article
- Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.Journal of viral hepatitis · 2024Article
- Test characteristics for combining non-invasive liver fibrosis staging modalities in individuals with Hepatitis C virus.Journal of viral hepatitis · 2024Article
- The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Review
- Scoping review of modelling studies assessing the impact of disruptions to essential health services during COVID-19.BMJ open · 2023Article
- COVID-19 in immunocompromised children: comparison of SARS-CoV-2 viral load dynamics between the first and third waves.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Burden of Chronic Obstructive Pulmonary Disease Attributable to Tuberculosis: A Microsimulation Study.American journal of epidemiology · 2023Article
- "We want everything in a one-stop shop": acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs.Harm reduction journal · 2022Article
- Dispensing of HIV and Hepatitis C Antivirals During COVID-19: An Interrupted Time-Series Analysis of U.S. National Data.American journal of preventive medicine · 2022Article
- A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probation.Health & justice · 2022Article
- Antibiotics Use in Hospitalised COVID-19 Patients in a Tertiary Care Centre: A Descriptive Cross-sectional Study.JNMA; journal of the Nepal Medical Association · 2022Article
- Projected Effects of Disruptions to Human Immunodeficiency Virus (HIV) Prevention Services During the Coronavirus Disease 2019 Pandemic Among Black/African American Men Who Have Sex With Men in an Ending the HIV Epidemic Priority Jurisdiction.Open forum infectious diseases · 2022Article
- A spotlight on HCV and SARS-CoV-2 co-infection and brain function.Pharmacology, biochemistry, and behavior · 2022Article
- COVID-19 and antimicrobial resistance: A cross-study.The Science of the total environment · 2022Review
- Dismantling War on Drugs Policies in COVID-19's Aftermath.American journal of public health · 2022Article
- The Negative Impact of COVID-19 in HCV, HIV, and HPV Surveillance Programs During the Different Pandemic Waves.Frontiers in public health · 2022Article
- Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.PloS one · 2022Article
- Higher Hepatitis C Cure Rates in a Patient-Centered Medical Home Compared to Specialist Care.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) pandemic disrupted access to and uptake of hepatitis C virus (HCV) care services in the United States. It is unknown how substantially the pandemic will impact long-term HCV-related outcomes.
methodsWe used a microsimulation to estimate the 10-year impact of COVID-19 disruptions in healthcare delivery on HCV outcomes including identified infections, linkage to care, treatment initiation and completion, cirrhosis, and liver-related death. We modeled hypothetical scenarios consisting of an 18-month pandemic-related disruption in HCV care starting in March 2020 followed by varying returns to pre-pandemic rates of screening, linkage, and treatment through March 2030 and compared them to a counterfactual scenario in which there was no COVID-19 pandemic or disruptions in care. We also performed alternate scenario analyses in which the pandemic disruption lasted for 12 and 24 months.
resultsCompared to the "no pandemic" scenario, in the scenario in which there is no return to pre-pandemic levels of HCV care delivery, we estimate 1060 fewer identified cases, 21 additional cases of cirrhosis, and 16 additional liver-related deaths per 100 000 people. Only 3% of identified cases initiate treatment and <1% achieve sustained virologic response (SVR). Compared to "no pandemic," the best-case scenario in which an 18-month care disruption is followed by a return to pre-pandemic levels, we estimated a smaller proportion of infections identified and achieving SVR.
conclusionsA recommitment to the HCV epidemic in the United States that involves additional resources coupled with aggressive efforts to screen, link, and treat people with HCV is needed to overcome the COVID-19-related disruptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.